Natera (NASDAQ:NTRA) Price Target Raised to $175.00

Natera (NASDAQ:NTRA) had its price target increased by TD Cowen from $155.00 to $175.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Other research analysts have also issued research reports about the company. Canaccord Genuity Group lifted their price target on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Leerink Partners lifted their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein lifted their price target on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $135.06.

Natera Trading Up 19.1 %

Shares of NTRA opened at $160.97 on Wednesday. Natera has a 52-week low of $49.97 and a 52-week high of $167.79. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The firm’s fifty day moving average is $126.04 and its two-hundred day moving average is $114.84. The stock has a market cap of $19.91 billion, a PE ratio of -91.46 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.88%. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the previous year, the company posted ($0.95) EPS. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. Research analysts forecast that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the transaction, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at approximately $24,927,655.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Michael Burkes Brophy sold 608 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $120.76, for a total value of $73,422.08. Following the completion of the transaction, the chief financial officer now directly owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the sale, the chief executive officer now owns 191,163 shares of the company’s stock, valued at approximately $24,927,655.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,881 shares of company stock valued at $3,733,983 in the last three months. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. purchased a new stake in Natera in the second quarter valued at approximately $28,000. Quarry LP raised its stake in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the last quarter. Covestor Ltd raised its stake in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new stake in shares of Natera during the third quarter worth approximately $70,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.